Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study. (October 2018) - Stiller, Charles A.
Highlights: Five-year relative survival of adults in Europe with bone cancer in 2000–2007 was 53%. Five-year relative survival of adults in Europe with soft-tissue cancer was 60%. Survival for both groups began to increase around 2005. The elderly and patients in Eastern Europe must share more fully in improved outcomes. European Reference Networks on rare cancers will have a vital role in future progress. Abstract: Background: Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still <60% by 1995-1999. There was large geographical survival variability, mainly for bone tumours, and survival decreased with increasing age at diagnosis. Methods: Data from 87 population-based cancer registries in 29 countries, extracted from the EUROCARE-5 database, were used to provide updated estimates of survival and describe trends in survival of adults with cancers of these sites across Europe. We calculated 5-year RS for patients diagnosed in 2000–2007. We estimated 5-year RS by the period approach to assess changes in survival between 1999–2001, 2002–2004 and 2005–2007, and provide reliable predictions for recently diagnosed patients. Results: Five-year RS was 60% for adults diagnosed with soft-tissue cancer in 2000–2007 and 53% for those with bone cancer. RS declined with increasing age at diagnosis, especially for bone cancer. Survival from bone cancer varied widely between European regions, from 63 to 62% in Northern and Central Europe to 39% in Eastern Europe. Inter-regional variation was much less for soft-tissue cancer. For both site groupings, there was little evidence of change in five-year RS up to 2002–2004, followed by increases of 3–4% during 2005–2007. Conclusions: Outcomes for adults with bone and soft-tissue cancer in Europe began to improve around 2005; new therapeutic developments are expected to result in further progress. Survival improvements already achieved must be brought more fully to elderly patients and those in Eastern Europe. European Reference Networks on rare cancers will have a vital role in future progress.